Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2011	Pharm Exec's 10th Annual Industry Audit A survey of the landscape of pharma financials over the past year, and a look at which companies rode the wave to the top of the industry in delivering value to shareholders.
Pharmaceutical Executive September 1, 2012 Bill Trombetta	Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players.
Pharmaceutical Executive September 1, 2014 Bill Trombetta	13th Annual Industry Audit After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.
Pharmaceutical Executive September 1, 2006 Bill Trombetta	Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers.
Pharmaceutical Executive September 1, 2005 Bill Trombetta	2005 Industry Audit Who's really on top in the pharmaceutical industry?
Pharmaceutical Executive June 1, 2009	Stealth Pharmas These noteworthy pharmas and biotechs generally fly under the radar (ergo "stealth") of the mainstream media.
Pharmaceutical Executive April 1, 2007 Bill Trombetta	Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes?
Pharmaceutical Executive September 1, 2014 William Looney	13 Years Right Pharm Exec's latest Industry Audit sticks to the series' longtime standard of emphasizing transparent indicators of shareholder value.
Pharmaceutical Executive January 1, 2014 Stan Bernard	The 7 Habits of Highly Effective Competitions Lessons to win in a shifting market dynamic
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Pharmaceutical Executive June 9, 2014 Cliff Kalb	The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard.
Pharmaceutical Executive September 1, 2012 William Looney	The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns.
Pharmaceutical Executive September 1, 2010 William Looney	The Coming Second Act Reinvention takes more than a pithy redraft of the strategy plan or mission statement; money, a change in business culture, and the mindset of thousands of employees is required too.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
Pharmaceutical Executive November 1, 2011	Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk.
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive July 1, 2012 William Looney	The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good.
Pharmaceutical Executive June 1, 2011	Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity?
Pharmaceutical Executive June 1, 2011	2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead.
The Motley Fool November 7, 2011 Dan Caplinger	Has Pfizer Become the Perfect Stock? The pharma giant still faces the challenge of patent expirations that could outpace its pipeline development.
Pharmaceutical Executive July 1, 2012	Emerging Pharma Leaders 2012 Meet 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history by doing better with less while tapping new opportunities from science and technology to build competitive scale?
Pharmaceutical Executive June 1, 2012	2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead.
Pharmaceutical Executive July 1, 2013 Looney et al.	Pharm Exec's 2013 Emerging Pharma Leaders Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what?
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
Pharmaceutical Executive January 1, 2009 Walter Armstrong	Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges.
Pharmaceutical Executive June 9, 2014 William Looney	Pharma 50 Trends: Past, Present, and Future Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
The Motley Fool October 18, 2010 Gerard Torres	Every Investor Should Know This Stock Tool Use DuPont analysis to breakdown the profitability of stocks.
Investment Advisor January 2007 Mark Tibergien	Analyze This Benchmark your financial advisory firm against itself, as well as the competition.
Pharmaceutical Executive March 1, 2006 Cacciotti & Shew	Pharma's Next Top Model: Slimmer Business Models After almost two decades of blockbuster-driven prosperity, the model for success in pharmaceuticals has broken down. The path forward, once clear, is no longer obvious.
Pharmaceutical Executive January 1, 2007 Walter Armstrong	Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy.
Pharmaceutical Executive October 1, 2006 Joanna Breitstein	"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival.
Pharmaceutical Executive January 1, 2011	The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs
Pharmaceutical Executive July 3, 2007 Walter Armstrong	Take Me to Your Leader Turnover in the top 10 pharmas has new CEOs racing to reinvent the way their companies do business. Running a large pharmaceutical company has becoming immensely complex, and requires a broad set of management skills. Even then, a CEO may never see a beloved molecule approved for drughood.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Pharmaceutical Executive July 10, 2014 William Looney	Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead.
Pharmaceutical Executive January 21, 2014 Tim Powell	Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
Chemistry World April 20, 2009 Phil Taylor	GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
Pharmaceutical Executive March 1, 2012 Sillup & Porth	Pharma & The Press Our eighth annual press audit finds the industry out of the crosshairs for now.
Chemistry World December 22, 2010 Sarah Houlton	Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US.
Pharmaceutical Executive December 1, 2013 Peter Young	2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better.
Pharmaceutical Executive September 1, 2006 Kieran Hartsough	Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool May 24, 2011 Andrew Tonner	Does Eli Lilly Deserve a Spot in Your Portfolio? A quick check of the numbers should help get us started.
Pharmaceutical Executive May 1, 2011 William Looney	Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.